Clinical trial · no report yet · Phase 1
MagnetisMM-30
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- NCT06215118 ↗
- Active, not recruiting
- Pfizer
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 11 | |
| X threads | 5 | |
| Podcasts | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Iberdomide
- Arms
- Part 1 Dose Escalation · Experimental
- Part 2 Dose Randomization · Experimental
- Enrollment
- 100
- Primary outcomes
- Part 1: Number of participants with dose limiting toxicity (DLT)
- Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
- Sponsor
- Pfizer with Bristol-Myers Squibb
- Start
- Feb 20, 2024
- Primary completion
- Nov 16, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06215118 · updated Sep 15, 2026